Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ERAS-007 + ERAS-601 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ERAS-007 | ASN007|ASN-007|ASN 007|ERAS007|ERAS 007 | ERK Inhibitor (pan) 21 | ERAS-007 (ASN007) is a small molecule that inhibits ERK1/2, which may result in decreased tumor cell proliferation and reduced tumor growth (PMID: 34337566). | |
ERAS-601 | ERAS 601|ERAS601 | SHP2 Inhibitor 20 | ERAS-601 inhibits SHP2, potentially resulting in decreased cell growth and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2669). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|